Status:
COMPLETED
Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer
Lead Sponsor:
Xijing Hospital of Digestive Diseases
Conditions:
Gastric Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serolog...
Eligibility Criteria
Inclusion
- Age between 18-70, both gender;
- The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy;
- Informed consent was obtained.
Exclusion
- The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc;
- Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc;
- Pregnant women;
- Primary tumors of other systems were diagnosed;
- Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis;
- Patients with mental illness;
- Patients who have received radiotherapy or surgery previously;
- Those with poor adherence or difficult to follow up.
Key Trial Info
Start Date :
May 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06031779
Start Date
May 1 2023
End Date
July 1 2024
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hosipital of Digestive Disease
Xi'an, Shaanxi, China, 710032